$TECH — AVOID 📊

$TECH — AVOID 📊 Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and biopro 🎯 Q2 2026 | Rev $0B | EPS $0.53 vs $0.53 ➖ 💡 Consensus likely prices in sustained premium growth and valuation, but the variant view is that the high PE (82.8x vs historical median 78.8x) embeds optimistic assumptions that are vulnerable to any growth hiccup, making the stock unattractively priced. 📉 Reward/Risk: 0:1 🏢 Business Quality: 6/10 - Adequate but not exceptional; high multiples reflect elevated expectations rather than demonstrated durable competitive advantages, and the health care sector context is neutral. 📊 Our read: AVOID. Full analysis → https://stockduty.xyz/s/TECH0622 Also in play: $AAPL $GOOGL $MSFT $AMZN $META $TSM

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and biopro